Barclays analyst Raimo Lenschow maintains ZoomInfo Technologies (NASDAQ:ZI) with a Overweight and raises the price target from $50 to $54.
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
The US National Institutes of Health has launched two clinical trials to test a new long-acting form of HIV PrEP in cisgender women and people who inject drugs. These mid-stage studies will evaluate the safety and pharmacokinetics of lenacapavir, a bi-annual injectable antiretroviral drug.
